RecruitingNCT05432739
Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study
Sponsor
Royal Marsden NHS Foundation Trust
Enrollment
500 participants
Start Date
Apr 7, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Patients under active investigation or surveillance for incidental lung nodules
- Age \> 18.
Exclusion Criteria4
- Active or previous diagnosis of malignancy (within 5 years preceding baseline scan).
- Inability to give informed consent.
- Active infection (including tuberculosis or fungal infection).
- Clinician-suspected or confirmed active or recent COVID-19 infection (less than 4 weeks before CT scan or required blood sampling date).
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05432739
Related Trials
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT046786483 locations
Virtual Agent Feasibility in Oncology Patients (NTT Data)
NCT066820131 location
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667100 locations
Empathic Communication Skills (ECS) Training
NCT0545684112 locations
Lung Cancer Screening in HIgh Risk nonsmokErs by Artificial inteLligence Device
NCT062954971 location